Cassava Sciences' Simufilam Trial Halted by FDA

Cassava Sciences' trial for simufilam in tuberous sclerosis complex-related epilepsy has been placed on full clinical hold by the FDA. The company needs to provide additional information and modify the protocol design. The updated timing for trial initiation depends on the company's ability to provide the requested information and the FDA's review. Cassava has $106.1 million in cash and cash equivalents, expected to support operations into 2027.